Want to see IN:LAURUSLABS full AI Analyst Report?
LAURUSLABS Stock Chart & Stats
₹1107.05
-₹1.35(-0.22%)
At close: 4:00 PM EST
₹1107.05
-₹1.35(-0.22%)
Day’s Range― - ―
52-Week Range₹722.00 - ₹1,530.30
Previous CloseN/A
Volume1.25M
Average Volume (3M)107.31K
Market Cap
₹819.37B
Enterprise Value₹763.54B
Total Cash (Recent Filing)₹633.80M
Total Debt (Recent Filing)₹22.12B
Price to Earnings (P/E)92.2
Beta0.92
Next Earnings
Jul 23, 2026EPS Estimate
4.47Next Dividend Ex-DateN/A
Dividend Yield0.15%
Share Statistics
EPS (TTM)12.68
Shares Outstanding539,856,570
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)10.11
Price to Sales (P/S)7.86
P/FCF Ratio137.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,130.00Price Target Upside2.07% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)20.51
Revenue Forecast (FY)₹78.92B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin RecoveryRevenue rebounded in FY2026 with net margin improving to ~13%, indicating restored pricing power or mix improvements and a recovery in core profitability. This strengthens durable earnings capacity and supports reinvestment and debt servicing over the next several quarters.
Improving Leverage And Asset GrowthLeverage has reduced materially and the equity base is rising, lowering financial risk and improving flexibility. Steady asset growth suggests investments are scaling operations, making the balance sheet more resilient to cyclical volatility over a multi-quarter horizon.
Diversified Pharma Manufacturing & CDMO CapabilitiesA mixed revenue model—APIs, finished dosage forms and CDMO—creates structural diversification and recurring contract revenue. Compliance-capable manufacturing for regulated markets is a durable competitive advantage that supports long-term customer relationships and stable demand.
Bears Say
Weak Free Cash Flow ConversionPersistent weak FCF and recent sharp decline reduce financial flexibility despite earnings gains. Heavy capex or working-capital absorption limits ability to de-lever, fund dividends or organic M&A, making the recovery more dependent on sustained cash conversion improvements.
Gross Margin Compression And Choppy GrowthA notable drop in gross margin implies structural cost pressure, price erosion, or adverse mix that can depress sustainable profitability. Combined with uneven revenue trends, this raises uncertainty about margin normalization and long-term earnings durability.
Meaningful Absolute Debt And Sensitivity To CashAlthough leverage ratios have improved, sizeable absolute debt means poor cash conversion or profit volatility could quickly strain liquidity. The balance sheet remains exposed if earnings or FCF slip, constraining strategic optionality over several quarters.
Laurus Labs Ltd. News
LAURUSLABS FAQ
What was Laurus Labs Ltd.’s price range in the past 12 months?
Laurus Labs Ltd. lowest stock price was ₹722.00 and its highest was ₹1530.30 in the past 12 months.
What is Laurus Labs Ltd.’s market cap?
Laurus Labs Ltd.’s market cap is ₹819.37B.
When is Laurus Labs Ltd.’s upcoming earnings report date?
Laurus Labs Ltd.’s upcoming earnings report date is Jul 23, 2026 which is in 21 days.
How were Laurus Labs Ltd.’s earnings last quarter?
Laurus Labs Ltd. released its earnings results on Apr 30, 2026. The company reported ₹5.2 earnings per share for the quarter, beating the consensus estimate of ₹4.974 by ₹0.226.
Is Laurus Labs Ltd. overvalued?
According to Wall Street analysts Laurus Labs Ltd.’s price is currently Undervalued.
Does Laurus Labs Ltd. pay dividends?
Laurus Labs Ltd. pays a Notavailable dividend of ₹1.2 which represents an annual dividend yield of 0.15%. See more information on Laurus Labs Ltd. dividends here
What is Laurus Labs Ltd.’s EPS estimate?
Laurus Labs Ltd.’s EPS estimate is 4.47.
How many shares outstanding does Laurus Labs Ltd. have?
Laurus Labs Ltd. has 539,856,570 shares outstanding.
What happened to Laurus Labs Ltd.’s price movement after its last earnings report?
Laurus Labs Ltd. reported an EPS of ₹5.2 in its last earnings report, beating expectations of ₹4.974. Following the earnings report the stock price went down -0.597%.
Which hedge fund is a major shareholder of Laurus Labs Ltd.?
Currently, no hedge funds are holding shares in IN:LAURUSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Laurus Labs Ltd.
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
LAURUSLABS Stock 12 Month Forecast
Average Price Target
₹1,130.00
▲(2.07% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―





